The study finds less than 1 in 4 go on to second-line treatment.

Therapies targeting extracellular matrix remodeling might hold the most promise.

Bildyos and Bilprevda have the same indications as the reference products Prolia and Xgeva and are expected to be available later this year.

Targeting S100A4 with a monoclonal antibody could comprehensively dampen disease-causing pathways, say drug developers.

Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.

Researchers suggest that access to treatment and socioeconomic resources can influence glycemic control and disparities in the management of patients with Type 1 diabetes.

Cadisegliatin acts in the liver to increase the activity of glucokinase, an enzyme that plays a role in regulating blood glucose levels.

Proposed premium increases in the ACA Marketplace for 2026 surge due to rising healthcare costs, specialty drug prices and subsidy uncertainties, according to a recent KFF analysis.

A new study shows Medicare can pay plans more fairly for caring for people from different racial and ethnic backgrounds without breaking the system.

Experts criticize the FDA's narrow COVID-19 vaccine approval, warning it limits access and undermines public health amid rising hospitalization rates.

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight.

Four other top officials at the public health agency have resigned, according to news reports.

Humana enhances value-based care for Medicare Advantage members with new partnerships, addressing rising musculoskeletal condition costs and improving patient outcomes.

Two of the studies are of controversial post-vaccination syndrome.

With healthcare costs climbing, Stuart will lead the nonprofit insurer’s push to keep coverage affordable for 6 million Californians.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with nutrition and lifestyle support, as well as prescriptions for medications.

Researchers from the University of Michigan have developed a skin patch that was able to accurately detect melanoma in tissue samples from mice.

The FDA suspends Ixchiq, the first approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S. market.

Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of 2025, with diabetes submissions to follow in 2026.

A study of patients with schizophrenia at a psychiatric hospital in China showed that focused group therapy in combination with antipsychotic medication is linked to improvement in depression and other aspects of mental health.

While prophylactic treatment is the standard treatment for severe hemophilia, its implementation can be complicated in patients who develop inhibitors

Although Medicare Advantage plan member satisfaction has dropped, areas for improvement have emerged in the form of digital innovations, according to the J.D. Power 2025 U.S. Medicare Advantage Study.

A new Business Group on Health survey finds that nearly a quarter of all employer healthcare spending (24%) went to pharmacy expenses in 2024, and employers forecast an 11% to 12% increase in pharmacy costs heading into 2026.

Here’s what you missed this week on Managed Healthcare Executive.